Copertina

A retrospective analysis of the use of candesartan for migraine prevention in adolescents

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Irene Patniyot, Ankona Banerjee, Kenneth Nobleza, Duc Nguyen, Deanna Duggan, Michelle Holick, Holly Dudley‐Harrell
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Memantine as a migraine prophylactic agent in adolescents: A retrospective analysis
di: M. Ismail K. Yousaf, et al.
Pubblicazione: (2025)

Behavioral interventions for migraine prevention: A systematic review and meta‐analysis
di: Jonathan R. Treadwell, et al.
Pubblicazione: (2025)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
di: Amy A. Gelfand
Pubblicazione: (2024)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
di: Jessica Ailani, et al.
Pubblicazione: (2024)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
di: Bilal Ahmed Rizvi, et al.
Pubblicazione: (2024)

Effectiveness and acceptability of oral migraine preventives: A prospective, observational study
di: Hedda S. Riise, et al.
Pubblicazione: (2026)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
di: Lawrence C. Newman, et al.
Pubblicazione: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
di: Rebecca Lindsay, et al.
Pubblicazione: (2024)

Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study
di: Seonyoung Kang, et al.
Pubblicazione: (2024)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
di: Jessica Ailani, et al.
Pubblicazione: (2026)

Do antithrombotic drugs have a role in migraine prevention? A systematic review
di: Federico De Santis, et al.
Pubblicazione: (2025)

A retrospective review of sex differences of white matter hyperintensities in brain MRI of patients with migraine
di: Ye Su, et al.
Pubblicazione: (2024)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
di: Alex Jaimes, et al.
Pubblicazione: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
di: Joanna K. Bougie, et al.
Pubblicazione: (2024)

Rising migraine incidence in adolescents despite stable prevalence in the US : A call for further investigation
di: Ali Reza Tavasoli, et al.
Pubblicazione: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
di: Julia Peris‐Subiza, et al.
Pubblicazione: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
di: Geneviève Tourigny‐Ruel, et al.
Pubblicazione: (2026)

Maternal and child mental health and incident migraine in adolescence: An “All Our Families” prospective cohort study
di: Kirsten Sjonnesen, et al.
Pubblicazione: (2026)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
di: Emmanuelle A. D. Schindler, et al.
Pubblicazione: (2025)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
di: Dawn C. Buse, et al.
Pubblicazione: (2024)

Substance use in a Dutch migraine cohort compared with the general population
di: Thomas C. van den Hoek, et al.
Pubblicazione: (2024)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
di: Shuu‐Jiun Wang, et al.
Pubblicazione: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Differential impact of migraine on severe maternal morbidity and postpartum readmissions: Insights from a national cohort study
di: Michelle T. Tram, et al.
Pubblicazione: (2026)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
di: David Kudrow, et al.
Pubblicazione: (2025)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
di: Serena Laura Orr, et al.
Pubblicazione: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

Reliability, validity, and responsiveness of the Arabic version of HIT ‐6 questionnaire in patients with migraine indicated for preventive therapy: A multi‐center study
di: Mona Hussein, et al.
Pubblicazione: (2024)

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
di: Gabriel Paiva da Silva Lima, et al.
Pubblicazione: (2025)

Retrofitted adult interventions aren't good enough: Why children and adolescents deserve tailored evidence‐based care for migraine in the emergency department
di: Serena L. Orr
Pubblicazione: (2026)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
di: Christopher C. Anderson, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
di: Andrew C. Charles, et al.
Pubblicazione: (2024)

Gepants for headache prevention in children and adolescents: A multicenter chart review study
di: Lauren Shin, et al.
Pubblicazione: (2025)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)